Abstract:Introduction: In preclinical cardiovascular safety pharmacology studies, statistical analysis of the rate corrected QT interval (QTc) is the focus for predicting QTc interval changes in the clinic. Modeling of a concentration/QTc relationship, common clinically, is limited due to minimal pharmacokinetic (PK) data in nonclinical testing. It is possible, however, to relate the average drug plasma concentration from sparse PK samples over specific times to the mean corrected QTc. We hypothesize that averaging drug plasma concentration and the QTc-rate relationship over time provides a simple, accurate concentration-QTc relationship bridging statistical and concentration/QTc modeling. Methods: Cardiovascular telemetry studies were conducted in non-human primates (NHP; n = 48) and canines (n = 8). Pharmacokinetic samples were collected on separate study days in both species. Average plasma concentrations for specific intervals (CAverage0-X) were calculated for moxifloxacin in canines and NHP using times corresponding to super-intervals for the QTc data statistical analysis. The QTc effect was calculated for each super-interval using a linear regression correction incorporating QT and HR data from the whole super-interval. The concentration QTc effects were then modeled. Results: In NHP, a 10.9 ± 0.06 ms (mean ± 95% CI) change in QTc was detected at approximately 1.5× the moxifloxacin plasma concentration that causes a 10 ms QTc change in humans, based on a 0-24 h super-interval. When simulating a drug without QT effects, mock, no effect on QTc was detected at up to 3× the clinical concentration. Similarly, in canines, a 16.6 ± 0.1 ms change was detected at 1.7× critical clinical moxifloxacin concentration, and a 0.04 ± 0.1 ms change was seen for mock. Conclusions: While simultaneous PK and QTc data points are preferred, practical constraints and the need for QTc averaging did not prevent concentration-QTc analyses. Utilizing a 0-24 h super-interval method illustrates a simple and effective method to address cardiovascular questions when preclinical drug exposures exceed clinical concentrations.

Nonpenetrating injuries of the neck and cerebrovascular accident.

Assessing QT prolongation in conscious dogs: validation of a beat-to-beat method

Origin of the Koreans: a population genetic study.

A "one‐step" approach to heart rate correction and statistical analysis applied to conscious dog QTc studies

A simple accurate method for concentration-QTc analysis in preclinical animal models

Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation

Quantum oscillations in magnetothermopower measurements of the topological insulator Bi2Te3.

Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium

Effects of Pratylenchus coffeae and Scutellonema bradys alone and in combination on guinea yam (Dioscorea rotundata).

Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone

Universal Correction for QT/RR Hysteresis

Translating QT interval prolongation from conscious dogs to humans

Circadian Rhythm of the Corrected QT Interval: Impact of Different Heart Rate Correction Models

Comparison of different QT correction methods for nonclinical safety assessment in ketamine-anesthetized Indian rhesus monkeys (Macaca mulatta)

The Effect of Sotalol on QTc and JTc During Movement

Treatment option for sperm- or oocyte-related fertilization failure: assisted oocyte activation following diagnostic heterologous ICSI.

Contact Lens Comfort.

Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes

Relevance of accurate QT correction in the assessment of long QT syndrome

Heart Rate Correction of the J-to-Tpeak Interval

Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model